Sk Biopharmaceuticals Co Ltd

Price Chart

Risk-Adjusted Performance

Sk Biopharmaceuticals Co Ltd (326030) Price Performance

Sk Biopharmaceuticals Co Ltd (326030) trades on KO in KRW. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at KRW98500.00, up 0.92% from the previous close.

Over the past year, 326030 has traded between a low of KRW88500.00 and a high of KRW140700.00. The stock has lost 4.4% over this period. It is currently 30.0% below its 52-week high.

Sk Biopharmaceuticals Co Ltd has a market capitalization of $7.64T, with a price-to-earnings ratio of 28.63.

About Sk Biopharmaceuticals Co Ltd

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.